Zhiyuan Niu

Zhiyuan Niu

Auto-generated profile, based on publicly available information

Zhiyuan Niu

Henan Engineering Technology Research Center for Advanced SynBio Medicine and Clinical Innovation Translation, School of Life Sciences and Technology, Henan Medical University, Xinxiang, Henan Province, PR China; Henan Engineering Research Center of Innovation for Synthetic Biology, School of Life Sciences and Technology, Henan Medical University, Xinxiang, Henan Province, PR China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
ZNZhiyuan Niu
Zhiyuan Niu
GCGuanxu Chen
Guanxu Chen
WCWei Chang
Wei Chang
PSPengyang Sun
Pengyang Sun
ZLZhixia Luo
Zhixia Luo
WZWuling Zhu
Wuling Zhu

5 February 2017 in The FEBS Journal
Verified
Journal Article
Closed access
ZNZhiyuan Niu
Zhiyuan Niu
JTJiajin Tang
Jiajin Tang
WZWenlong Zhang
Wenlong Zhang
YCYongjun Chen
Yongjun Chen
YHYahong Huang
Yahong Huang
PSPingping Shen
Pingping Shen

18 September 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
ZNZhiyuan Niu
Zhiyuan Niu
MWMengjun Wang
Mengjun Wang
YYYangchun Yan
Yangchun Yan
XJXinru Jin
Xinru Jin
LNLinwei Ning
Linwei Ning
WZWuling Zhu
Wuling Zhu
The human-derived NK-92 cell–based CAR-NK therapy exhibits inconsistency with overall suboptimal efficacy and rapid in vivo clearance of CAR-NK92 cells in cancer patients. Analysis indicates that although pre-existing IgM in healthy individuals (n = 10) strongly recognizes both NK-92 and CAR-NK92 cells, IgG and IgE do not. However, only a subset of cancer patients (3/8) exhibit strong IgM recognition of these cells, with some (2/8) showing pre-existing IgG recognition. These results suggest a natural immunoreactivity between NK-92 and CAR-NK92 cells and pre-existing human Abs. Furthermore, the therapy’s immunogenicity is evidenced by enhanced IgG and IgM recognition postinfusion of CAR-NK92 cells. We also confirmed that healthy plasma’s cytotoxicity toward these cells is reduced by complement inhibitors, suggesting that Abs may facilitate the rapid clearance of CAR-NK92 cells through complement-dependent cytotoxicity. Given that NK-92 cells lack known receptors for IgG and IgM, identifying and modifying the recognition targets for these Abs on NK-92 and CAR-NK92 cells may improve clinical outcomes. Moreover, we discovered that the 72nd amino acid of the NKG2D receptor on NK-92 cells is alanine. Previous studies have demonstrated polymorphism at the 72nd amino acid of the NKG2D on human NK cells, with NKG2D72Thr exhibiting a superior activation effect on NK cells compared with NKG2D72Ala. We confirmed this conclusion also applies to NK-92 cells by in vitro cytotoxicity experiments. Therefore, reducing the immunoreactivity and immunogenicity of CAR-NK92 and directly switching NK-92 bearing NKG2D72Ala to NKG2D72Thr represent pressing challenges in realizing NK-92 cells as qualified universal off-the-shelf cellular therapeutics.

27 April 2020 in Molecular Immunology
Verified
Journal Article
Closed access
HZHuiyong Zhang
Huiyong Zhang
WXWenjiao Xia
Wenjiao Xia
LCLiang Chen
Liang Chen
XWXiaoyin Wang
Xiaoyin Wang
LZLingtong Zhi
Lingtong Zhi
WZWuling Zhu
Wuling Zhu

17 July 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
YLYunwei Lou
Yunwei Lou
SJShan Jiang
Shan Jiang
MSMiaomiao Song
Miaomiao Song
HWHan Wang
Han Wang
MHMeijuan Han
Meijuan Han
Hui WangHui Wang
Hui Wang
Intestinal epithelial cells (IECs) at the internal/external interface orchestrate the mucosal immune response, and IEC dysfunction has been linked to multiple inflammatory diseases, including inflammatory bowel disease. In this study, we found that a member of the TNF-α–induced protein 8 (TNFAIP8 or TIPE) family called TIPE1 is indispensable for maintaining epithelial cell barrier integrity and homeostasis under inflammatory conditions. TIPE1-deficient mice, or chimeric mice that were deficient in TIPE1 in their nonhematopoietic cells, were more sensitive to dextran sulfate sodium–induced experimental colitis; however, TIPE1 deficiency had no impact on the development of inflammation-associated and sporadic colorectal cancers. Mechanistically, TIPE1 prevented experimental colitis through modulation of TNF-α–dependent inflammatory response in IECs. Importantly, genetic deletion of both TIPE1 and its related protein TNFAIP8 in mice led to the development of spontaneous chronic colitis, indicating that both of these two TIPE family members play crucial roles in maintaining intestinal homeostasis. Collectively, our findings highlight an important mechanism by which TIPE family proteins maintain intestinal homeostasis and prevent inflammatory disorders in the gut.

2 August 2022 in BioDesign Research
Verified
Journal Article
Open access
PDF file
ZNZhiyuan Niu
Zhiyuan Niu
ZLZhixia Luo
Zhixia Luo
PSPengyang Sun
Pengyang Sun
LNLinwei Ning
Linwei Ning
XJXinru Jin
Xinru Jin
WZWuling Zhu
Wuling Zhu
Camelid single-domain antibody fragments (nanobodies) are an emerging force in therapeutic biopharmaceuticals and clinical diagnostic reagents in recent years. Nearly all nanobodies available to date have been obtained by animal immunization, a bottleneck restricting the large-scale application of nanobodies. In this study, we developed three kinds of gene designated-region pan-editing (GDP) technologies to introduce multiple mutations in complementarity-determining regions (CDRs) of nanobodies in vitro. Including the integration of G-quadruplex fragments in CDRs, which induces the spontaneous multiple mutations in CDRs; however, these mutant sequences are highly similar, resulting in a lack of sequences diversity in the CDRs. We also used CDR-targeting traditional gRNA-guided base-editors, which effectively diversify the CDRs. And most importantly, we developed the self-assembling gRNAs, which are generated by reprogrammed tracrRNA hijacking of endogenous mRNAs as crRNAs. Using base-editors guided by self-assembling gRNAs, we can realize the iteratively diversify the CDRs. And we believe the last GDP technology is highly promising in immunization-free nanobody library construction, and the full development of this novel nanobody discovery platform can realize the synthetic evolution of nanobodies in vitro.